Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction

BACKGROUND: Aromatase inhibitors are widely used in the treatment of oestrogen receptor-positive post-menopausal breast cancer. These patients may also be receiving the bisphosphonate, zoledronic acid (ZA) to prevent bone loss or reduce skeletal morbidity in the setting of advanced disease. The pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Neville-Webbe, H L, Coleman, R E, Holen, I
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844031/
https://www.ncbi.nlm.nih.gov/pubmed/20160726
http://dx.doi.org/10.1038/sj.bjc.6605579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844031/
https://www.ncbi.nlm.nih.gov/pubmed/20160726
http://dx.doi.org/10.1038/sj.bjc.6605579

Ejemplares similares